This MedLibrary.org supplementary page on Lupus nephritis is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
| Lupus nephritis Classification and external resources |
|
| ICD-10 | N08.5 |
|---|---|
| ICD-9 | 583.81 |
| MedlinePlus | 000481 |
| eMedicine | med/1597 |
| MeSH | D008181 |
Lupus nephritis is an inflammation of the kidney caused by systemic lupus erythematosus (SLE), a disease of the immune system. Apart from the kidneys, SLE can also damage the skin, joints, nervous system and virtually any organ or system in the body.
Contents |
Signs and symptoms
Sufferers of lupus nephritis may or may not have symptoms of kidney disease, but it can manifest itself through weight gain, high blood pressure, darker foamy urine or swelling around the eyes, legs, ankles or fingers.
Histologically a wire-loop lesion will be present. The wire loop lesion is a glomerular capillary loop with subendothelial immune complex deposition that is circumferential around the loop.
Furthermore, patients may suffer from other symptoms of lupus unrelated to kidney function. Such symptoms can include arthritis, fevers, gastro-intestinal disturbances, headaches, fatigue, and fluid in the joints.
Diagnosis
The diagnosis of lupus nephritis depends on blood tests, urinalysis, X-rays, ultrasound scans of the kidneys, and a kidney biopsy.
The World Health Organization has divided lupus nephritis into five classes based on the biopsy. This classification was defined in 1982 and revised in 1995.[1]
- Class I is minimal mesangial glomerulonephritis which is histologically normal on light microscopy but with mesangial deposits on electron microscopy.
- Class II is based on a finding of mesangial proliferative lupus nephritis. This form typically responds completely to treatment with corticosteroids.
- Class III is focal proliferative nephritis and often successfully responds to treatment with high doses of corticosteroids.
- Class IV is diffuse proliferative nephritis. This form is mainly treated with corticosteroids and immunosuppressant drugs.
- Class V is membranous nephritis and is characterized by extreme edema and protein loss.
- Class VI Glomerulosclerosiscitation needed
Medicines that decrease swelling, lower blood pressure, and decrease inflammation by suppressing the immune system: Patients may need to monitor intake of protein, sodium, and potassium. Patients with severe disease should restrict their sodium intake to 2 grams per day and limit fluid as well. Depending on the histology, renal function and degree of proteinuria, patients may require steroid therapy or chemotherapy regimens such as cyclophosphamide, azathioprine, mycophenolate mofetil, or cyclosporine.
The medical therapy for lupus nephritis depends on the severity of the disease. For mild disease, corticosteroids are, in general, prescribed. More severe disease requires treatment with immunosuppressant agents. The two most commonly-used agents are mycophenolate mofetil and intravenous cyclophosphamide. One recent study compared these two drugs.[2] The authors showed that patients with Class III or IV disease are more likely to benefit from mycophenolate mofetil as compared to cyclophosphamide. However, a larger study by the same authors that directly compared these therapies did not show that Mycophenolate was superiour to cyclophosphamide except in non-caucasian non-asian patients[1]. In caucasian or asian patients both treatments worked equally well. There was no overall difference in safety in this trial, although cyclophosphamide may induce permanent infertility in young women, which is a significant drawback. As a result, mycophenolate mofetil is now considered to be an alternative therapy for this disease.
References
- ^ Weening JJ, D'Agati VD, Schwartz MM, et al (2004), "The classification of glomerulonephritis in systemic lupus erythematosus revisited", J. Am. Soc. Nephrol. 15(2): 241–50, PMID 14747370, <http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=14747370>
- ^ Ginzler EM, Dooley MA, Aranow C, et al (2005), "Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis", N. Engl. J. Med. 353(21): 2219–28, doi:, PMID 16306519
External links
- London Lupus Centre - Treatment, Diagnosis, Research
- Lupus Foundation of America, Inc.
- Lupus Research Institute
- S.L.E. Lupus Foundation
- Lupus International
|
|||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 4 September 2008, at 16:36.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Lupus nephritis".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.